Cargando…

Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

BACKGROUND: We sought to evaluate prognostic factors affecting overall survival (OS), and to investigate the role of palliative chemotherapy using propensity score-based weighting, in patients with advanced small bowel adenocarcinoma (SBA). METHODS: Data from a total of 91 patients diagnosed with ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, Dong Hoe, Yun, Sung-Cheol, Hong, Yong Sang, Ryu, Min-Hee, Lee, Jae-Lyun, Chang, Heung-Moon, Ryoo, Baek-Yeol, Kang, Yoon-Koo, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125281/ https://www.ncbi.nlm.nih.gov/pubmed/21619586 http://dx.doi.org/10.1186/1471-2407-11-205

Ejemplares similares

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2016)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients
por: Seo, Seung Hee, et al.
Publicado: (2016)

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
por: Seo, Seyoung, et al.
Publicado: (2016)

Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy
por: Seo, Seyoung, et al.
Publicado: (2019)

Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study
por: Park, Kwonoh, et al.
Publicado: (2017)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
por: Yoo, Changhoon, et al.
Publicado: (2016)

A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia
por: Kim, Hyun Woo, et al.
Publicado: (2006)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Prognostic factors in children with extracranial germ cell tumors treated with cisplatin-based chemotherapy
por: Kim, Jinsup, et al.
Publicado: (2015)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2020)

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas
por: Choi, Young Bae, et al.
Publicado: (2016)

Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
por: Park, Sook Ryun, et al.
Publicado: (2016)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
por: Lee, Jae Woo, et al.
Publicado: (2018)

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
por: Lee, Gyeong-Won, et al.
Publicado: (2003)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Anesthetic concerns during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: Ryu, Jung-Hee, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis
por: Shin, Young Seob, et al.
Publicado: (2022)

Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer
por: Paik, Kwang Hyun, et al.
Publicado: (2006)

Stereotactic body radiation therapy for locally advanced pancreatic cancer
por: Jung, Jinhong, et al.
Publicado: (2019)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study
por: Park, Jongha, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_pl2v7qv00ea2q8mt5ublca6518